CliffBio
biologic

Piasky

crovalimab-akkz

Loss of exclusivityJune 2036projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand namePiasky
Active ingredientcrovalimab-akkz
Strength340MG/2ML (170MG/ML)
Dosage formInjection
RouteIntravenous, Subcutaneous
ModalityBiologic
FDA approvalJune 2024
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.